目的：闡述防耐藥突變濃度（MPC）和耐藥突變選擇窗理論（MSW）及該理論最新研究進(jìn)展。方法：查閱近10年來國(guó)內(nèi)外相關(guān)文獻(xiàn)資料進(jìn)行整理歸納。結(jié)果與結(jié)論：通過近年報(bào)道的體內(nèi)外實(shí)驗(yàn)結(jié)果證明MPC和MSW是評(píng)價(jià)抗菌藥物防細(xì)菌耐藥能力的新指標(biāo)。在應(yīng)用抗菌藥物時(shí)，應(yīng)盡量縮小突變選擇窗，力爭(zhēng)遏制和延緩細(xì)菌耐藥突變。除選擇更理想的藥物、調(diào)整藥物劑量外， 聯(lián)合用藥在理論上講也是一條安全、有效的用藥途徑。AUC₂₄／MPC，C _max ／MPC 作為防止耐藥突變的預(yù)測(cè)指標(biāo)優(yōu)于AUC₂₄／MIC。根據(jù)防耐藥突變理論選擇應(yīng)用抗感染藥物為延緩耐藥提出了新的策略。

To review the recent research of mutant prevention concentration (MPC) and the latest progress. Reviews related to MPC in the recent ten years were reported in this paper. All these in vitro and in vivo studies indicated that MPC and mutant selective window (MSW) were new indexes to evaluate the antimicrobial resistance. During application of antibiotics, narrowing or closing the MSW, restraining and deplaying the bacteria-resistant mutant should try to be made. Besides selecting an ideal drug and optimizing the proper dosage, the combination therapy may be a safe and effective way to inhibit the development of resistance. AUC^{24/MPC is more appropriate than AUC24/MIC for predicting the restriction of resistant mutant emergence. It offers the ideal and new strategy for restricting resistant mutants and delaying antimicrobial resistance.}